1132671-96-5

Basic information

• Product Name: (2S,4S,5S,7S)-5-azido-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-8-methyl-nonanoic acid [3(R)- and 3(S)-(tetrahydro-furan-3-ylmethyl)]-amide
• Synonyms: (2S,4S,5S,7S)-5-azido-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-8-methyl-nonanoic acid [3(R)- and 3(S)-(tetrahydro-furan-3-ylmethyl)]-amide
• CAS NO: 1132671-96-5
• Molecular Weight: 562.75
• Mol File: 1132671-96-5.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (2S,4S,5S,7S)-5-azido-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-8-methyl-nonanoic acid [3(R)- and 3(S)-(tetrahydro-furan-3-ylmethyl)]-amide(CAS DataBase Reference)
• NIST Chemistry Reference: (2S,4S,5S,7S)-5-azido-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-8-methyl-nonanoic acid [3(R)- and 3(S)-(tetrahydro-furan-3-ylmethyl)]-amide(1132671-96-5)
• EPA Substance Registry System: (2S,4S,5S,7S)-5-azido-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-8-methyl-nonanoic acid [3(R)- and 3(S)-(tetrahydro-furan-3-ylmethyl)]-amide(1132671-96-5)

Safety Data

• Hazardous Substances Data: 1132671-96-5(Hazardous Substances Data)

Upstream product

• 324763-46-4 (3S,5S)-5-{(1S,3S)-1-azido-3-{[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl}-4-methylpentyl}-dihydro-3-(1-methylethyl)furan-2(3H)-one 
• 165253-31-6 (tetrahydro-3-furanyl)methylamine 

Downstream Products

• 1132671-94-3 (2S,4S,5S,7S)-5-azido-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-8-methyl-nonanoic acid [3(S)-(tetrahydro-furan-3-ylmethyl)]-amide 
• 1132671-92-1 (2S,4S,5S,7S)-5-azido-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-8-methyl-nonanoic acid [3(R)-(tetrahydro-furan-3-ylmethyl)]-amide 

Relevant articles and documents

ORGANIC COMPOUNDS

Disclosed are δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amide compounds of formula (I)and the salts thereof, having renin-inhibiting properties. Also disclosed are pharmaceutical compositions comprising these compounds and methods of administering them for the treatment of hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, unstable coronary syndrome, diastolic dysfunction, chronic kidney disease, hepatic fibrosis, complications resulting from diabetes, such as nephropathy, vasculopathy and neuropathy, diseases of the coronary vessels, restenosis following angioplasty, raised intra-ocular pressure, glaucoma, abnormal vascular growth, hyperaldosteronism, cognitive impairment, alzheimers, dementia, anxiety states and cognitive disorders.